Cardiol Therapeutics Inc.
CRDL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $34 |
| Gross Profit | $0 | $0 | $0 | -$34 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,787 | $2,732 | $3,757 | $2,939 |
| G&A Expenses | $5,368 | $4,919 | $4,647 | $0 |
| SG&A Expenses | $5,368 | $4,919 | $4,647 | $3,969 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $26 | $25 | $25 | $0 |
| Operating Expenses | $10,180 | $7,676 | $8,429 | $6,908 |
| Operating Income | -$10,180 | -$7,676 | -$8,429 | -$6,942 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $216 | -$678 | $141 | $1,259 |
| Pre-Tax Income | -$9,964 | -$8,354 | -$8,288 | -$5,683 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,964 | -$8,354 | -$8,288 | -$5,683 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.1 | -0.1 | -0.12 |
| % Growth | -20% | 0% | 16.7% | – |
| EPS Diluted | -0.12 | -0.1 | -0.1 | -0.12 |
| Weighted Avg Shares Out | 84,727 | 82,653 | 82,609 | 69,841 |
| Weighted Avg Shares Out Dil | 84,727 | 82,653 | 82,609 | 69,841 |
| Supplemental Information | – | – | – | – |
| Interest Income | $122 | $181 | $248 | $307 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $26 | $25 | $25 | $34 |
| EBITDA | -$9,939 | -$7,651 | -$8,404 | -$5,649 |
| % Margin | – | – | – | – |